Theriva™ biologics announces presentation describing next generation oncolytic adenovirus vcn-12 at the 32nd annual congress of the european society of gene & cell therapy (esgct)

- preclinical data for vcn-12, the next candidate from theriva's vcn-x discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects -

TOVX Ratings Summary

TOVX Quant Ranking